NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab — Stella

Home/Relapsed Neuroblastoma/

View on ClinicalTrials.gov

Recruiting

Back to Relapsed Neuroblastoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Nationwide Children's Hospital, Columbus, Ohio

Key details

Phase

Early testing / Safety & dosing

Sponsor

Nationwide Children's Hospital

Enrollment target

~31 participants

Started

September 2022

Primary completion

December 2026

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.